The National Agency for Food and Drug Administration and Control (NAFDAC) has ordered the recall and withdrawal of substandard batches of Annmox and Jawamox Amoxicillin oral suspensions currently in circulation across the country.
In Public Alert No. 35/2025, issued on Friday, the agency listed the affected products as Annmox (125mg/5ml) Batch No. 360M, and Jawamox (125mg/5ml) Batch Nos. 4231M and 4290M.
The suspensions, manufactured by Jawa International Limited, Isolo Industrial Estate, Lagos, reportedly failed quality tests, showing low Active Pharmaceutical Ingredient (API) content.
NAFDAC warned that the compromised API levels render the drugs ineffective for treating bacterial infections, exposing patients — particularly children — to prolonged illness, treatment failure, and increased risk of antimicrobial resistance.
“The identified batches failed laboratory analysis and do not meet the required quality specifications for API content,” the agency said.
It noted that ineffective antibiotic therapy could result in complications that may become life-threatening.
Healthcare providers, pharmacies, and distributors have been directed to stop dispensing the affected products and return them through approved recall channels.
Consumers are advised to check batch numbers carefully and report any suspected substandard medicines.
Complaints and verification reports can be sent via 0800-162-3322 or emailed to sf.alert@nafdac.gov.ng.
NAFDAC reaffirmed its commitment to ensuring that medicines in circulation meet safety and quality standards and urged the public to remain vigilant
